A large observational study successfully validates clinical outcome measures in CDKL5 deficiency disorder, revealing severe early-onset epilepsy with median seizure onset at 1.5 months. This research establishes crucial infrastructure for evaluating emerging targeted therapies in this rare epileptic encephalopathy.